title: A pilot study: longer duration of posttransplant hepatitis C virus therapy may increase the sustained response rate.
abstract: BACKGROUND
  Although end of treatment virological responses are similar in posttransplant patients with recurrent chronic hepatitis C virus infection and nontransplant patients, the sustained virological response rate is lower in the posttransplant setting. We investigated the efficacy of a longer duration (3 years) of therapy.
  
  
  METHODS
  Thirteen patients with biopsy-proven recurrent hepatitis C were included in the study. In the first year of therapy, all patients were treated with a standard regimen of interferon alpha 2b 3MU 3 times in a week plus ribavirin (800 to 1000 mg/d). After the availability of pegylated interferon, patients were converted to pegylated interferon (1.5 microg/kg body weight). Hepatitis C virus RNA was evaluated at months 3, 6, 9, 12, 24, 36, and 42. If hepatitis C virus RNA was negative at month 12, the patients continued treatment for 36 months.
  
  
  RESULTS
  Hepatitis C virus RNA was negative in six patients at 12 months, including two who became hepatitis C virus RNA negative after 3 months; two, after 6 months; and two, after 12 months of therapy. Those six continued treatment completing 3 years of treatment with a sustained virological response. Four of those six patients with sustained virological response required colony-stimulating factors during treatment.
  
  
  CONCLUSIONS
  Although the hepatitis C virus RNA status of patients at 12 weeks is a good marker to predict a sustained virological response in the nontransplant setting, it is not valid in posttransplant patients. A prolonged duration of therapy for patients who are viral responders at 12 months may prevent recurrence and increase the sustained virological response rate.
authors.affiliation: Department of Gastroenterology, Ege University, Izmir, Turkey.
authors.forename: Z
authors.initials: Z
authors.lastname: Karasu
authors.forename: S
authors.initials: S
authors.lastname: Akay
authors.forename: F
authors.initials: F
authors.lastname: Yilmaz
authors.forename: U
authors.initials: U
authors.lastname: Akarca
authors.forename: G
authors.initials: G
authors.lastname: Ersoz
authors.forename: F
authors.initials: F
authors.lastname: Gunsar
authors.forename: M
authors.initials: M
authors.lastname: Kilic
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007249:Inflammation / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011183:Postoperative Complications / Q000821:virology*; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral